𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Identification and characterization of autocrine-motility-factor-like activity in oral squamous-cell-carcinoma cells

✍ Scribed by Akira Ishisaki; Shinichiro Oida; Fumio Momose; Teruo Amagasa; Koichi Rikimaru; Hidenori Ichijo; Satoshi Sasaki

Publisher
John Wiley and Sons
Year
1994
Tongue
French
Weight
783 KB
Volume
59
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

A human oral squamous‐cell‐carcinoma cell line, HOC313, was found to produce a factor which stimulates cell motility in an autocrine manner. The motility factor of HOC313 cells also promoted the locomotory activity of B16 murine melanoma cells reported to be sensitive to autocrine motility factor (AMF). HOC313 cells were found to express a large amount of AMF receptor mRNA. In addition, the cell motility activity of HOC313 cells was completely blocked by pertussis toxin, a known inhibitor of AMF activity, suggesting that the motility factor of HOC313 cells may be AMF or a closely related factor. Immunocytochemical analysis has revealed that the AMF‐like factor of HOC313 cells diminishes the cell‐surface expression of adhesive molecule E‐cadherin. These results suggest that down‐regulation of E‐cadherin may be involved in the cell‐motility activity induced by the AMF‐like factor of HOC313 cells.

📜 SIMILAR VOLUMES

Expression of autocrine motility factor
Expression of autocrine motility factor receptor in human esophageal squamous cell carcinoma
✍ Kentaro Maruyama; Hideomi Watanabe; Hitoshi Shiozaki; Takuya Takayama; Junji Gof 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 French ⚖ 796 KB

Autocrine motility factor and its receptor (gp78) have been shown to play an important role in tumor cell migration, invasion and metastasis. We have detected gp78 expression in buffered-formalin-fixed, paraffin-embedded sections of esophageal squamous cell carcinomas using an anti-gp78 monoclonal a

Antitumor activity of satraplatin in cis
Antitumor activity of satraplatin in cisplatin-resistant oral squamous cell carcinoma cells
✍ Yukio Yamano; Masashi Shiiba; Kenji Negoro; Ken Nakatani; Atsushi Kasamatsu; Mas 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 529 KB

## Abstract ## __Background.__ The aim of the current study was to identify the antitumor activity of satraplatin in paired cisplatin (CDDP)‐resistant oral squamous cell carcinoma (OSCC) cell line and its parental cell line. ## __Methods.__ CDDP‐resistant (KB‐R) cells and parental cells (KB) pai

KIT receptor activation by autocrine and
KIT receptor activation by autocrine and paracrine stem cell factor stimulates growth of merkel cell carcinoma in vitro
✍ Konstantin Krasagakis; Irene Fragiadaki; Maria Metaxari; Sabine Krüger-Krasagaki 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 432 KB

## Abstract The co‐expression of KIT receptor and its ligand stem cell factor (SCF) has been reported in biopsy specimens of Merkel cell carcinoma (MCC). However, the functional role of SCF/KIT in the pathogenesis of this aggressive tumor has not been elucidated. The present study reports expressio

Prognostic factors in oral cavity and or
Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma : The impact of tumor-associated macrophages
✍ Benjamin Marcus; Douglas Arenberg; Julia Lee; Celina Kleer; Douglas B. Chepeha; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 736 KB

## Abstract ## BACKGROUND The survival of patients with head and neck squamous cell carcinoma (HNSCC) remains unaffected despite recent therapeutic advances. To reverse this trend, reliable and clinically applicable markers of tumor aggressiveness must be identified. One such marker may be the tum

Induction of heparin-binding EGF-like gr
Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells
✍ Faye M. Johnson; Babita Saigal; Nicholas J. Donato 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 459 KB

Imatinib mesylate is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit kinases. Inhibition of BCR-ABL and c-kit accounts for its clinical activity in leukemia and sarcoma, respectively. In this report, we describe other cellular targets for imatinib.